GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

SPORE in Brain Cancer

$2,088,365
Frederick F Lang · University Of Tx Md Anderson Can Ctr · P50 · FY2024 · CA

Strategies for Cancer Immunotherapy Development: Preclinical Studies

$2,088,156
Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

SPORE in Breast Cancer

$2,088,032
Jennifer A Pietenpol · Vanderbilt University Medical Center · P50 · FY2020 · CA

Clinical evaluation of a novel AKT/PDK1 inhibitor, PHT-427, for the treatment of multi-field actinitc keratoses

$2,085,765
Garth Powis · Phusis Therapeutics, Inc. · R44 · FY2025 · CA

University of Wisconsin Prostate SPORE

$2,085,688
David F Jarrard · University Of Wisconsin-Madison · P50 · FY2024 · CA

The University of Texas MD Anderson Cancer Center SPORE in Melanoma

$2,083,190
Patrick Hwu · University Of Tx Md Anderson Can Ctr · P50 · FY2019 · CA

Detection, prevention and treatment of acute myeloid leukemia (AML) relapse.

$2,079,438
Christopher Hourigan · National Heart, Lung, And Blood Institute · ZIA · FY2018 · HL

Computational studies of cancer immunotherapy

$2,073,990
Eytan Ruppin · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA

The University of Texas MD Anderson Cancer Center SPORE in Melanoma

$2,070,386
Michael Davies · University Of Tx Md Anderson Can Ctr · P50 · FY2023 · CA

Preclinical drug development in pancreatic cancer

$2,069,338
Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

SPORE in Brain Cancer

$2,069,263
Frederick F Lang · University Of Tx Md Anderson Can Ctr · P50 · FY2019 · CA

Systems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule Drugs

$2,067,796
Peter Karl Sorger · Harvard Medical School · U54 · FY2019 · CA

Molecularly Targeted Radiosensitization of Locally Advanced Cancers

$2,066,150
Theodore S Lawrence · University Of Michigan At Ann Arbor · P50 · FY2023 · CA

Centers for Cancer Systems Therapeutics (CaST)

$2,065,461
Andrea Califano · Columbia University Health Sciences · U54 · FY2019 · CA

Brain Tumor Clinical and Clinical Research Program

$2,062,121
Mark Gilbert · Division Of Basic Sciences - Nci · ZID · FY2019 · CA

University of Wisconsin Prostate SPORE

$2,061,062
David F Jarrard · University Of Wisconsin-Madison · P50 · FY2023 · CA

The University of Texas MD Anderson Cancer Center SPORE in Melanoma

$2,058,691
Michael Davies · University Of Tx Md Anderson Can Ctr · P50 · FY2022 · CA

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs

$2,058,319
Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Deciphering LKB1-associated immunotherapy resistance in lung adenocarcinoma (LUAD)

$2,055,632
Haian Fu · Emory University · P01 · FY2024 · CA

SPORE in Brain Cancer

$2,051,421
Frederick F Lang · University Of Tx Md Anderson Can Ctr · P50 · FY2023 · CA

SPORE in Brain Cancer

$2,051,421
Frederick F Lang · University Of Tx Md Anderson Can Ctr · P50 · FY2022 · CA

SPORE in Brain Cancer

$2,051,421
Frederick F Lang · University Of Tx Md Anderson Can Ctr · P50 · FY2021 · CA

Head and Neck Cancer SPORE at the University of Wisconsin

$2,049,112
Paul M Harari · University Of Wisconsin-Madison · P50 · FY2024 · CA

Centers for Cancer Systems Therapeutics (CaST)

$2,041,589
Andrea Califano · Columbia University Health Sciences · U54 · FY2020 · CA

Preclinical GEM and GDA Models of Primary and Metastatic Melanoma

$2,041,466
Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA